ARRY 797

Drug Profile

ARRY 797

Alternative Names: ARRY-371797; ARRY-797

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Class Anti-inflammatories; Antineoplastics; Non-opioid analgesics; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dilated cardiomyopathy
  • No development reported Cancer; Dental pain
  • Discontinued Ankylosing spondylitis; Musculoskeletal pain; Rheumatoid arthritis

Most Recent Events

  • 09 Aug 2017 Array plans to initiate a phase III study of ARRY 797 in Dilated cardiomyopathy in late 2017
  • 15 Dec 2016 Biomarkers information updated
  • 30 Aug 2016 Adverse events data from a phase II trial in Dilated cardiomyopathy released by Array BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top